INTRODUCTION AND OBJECTIVES: Non muscle invasive bladder cancer (NMIBC) has a highly variable clinical behaviour not adequately predicted by their histological grade and clinical parameters. Some are indolent; others quickly progress to muscle-invasive disease. The discrepancy between phenotype and genotype is compounded further by interobserver variability in pathological grading. There is an unmet need to improve the prediction of NMIBC's behavior.
METHODS: Whole transcriptomic (WT) analysis of 178 bladder tumours (158 NMIBC and 20 MIBC or metastatic) was performed from formalin fixed paraffin embedded (FFPE) tissues incorporating messenger RNA expression, splice variants, gene fusion, mutation detection and immune checkpoint inhibitor cascades. CTLA, PD-1, LAG3, TIM3, TIGIT and B7 were compiled as an index with all major genes in the cascade included. These data were integrated and tested for correlations with both pathological grading and clinical outcomes. Conventional pathological grading for both WHO 1973 (grade 1, 2 and 3) and 2004 (low grade-LG vs high grade-HG) classifications was reviewed by 3 different expert uro-pathologists and kappa statistic for interobserver variability was calculated. For validation we used an independent RNASequencing dataset (n¼209, Hedegaard et al. 2016 Cancer Cell) ) signalling systems, in particular, GTPase regulation (p¼0.002), respiratory cycle genes (p¼0.004) and a HOX cluster (p¼0.005). MGRI independently predicted progression to MIBC (n¼138, HR¼2.96, ). Five year progression-free survival in a combined data set (n¼347) differed significantly for MGRI1 (100%) vs MGRI2 (92.2%) vs MGRI3 (73.5%, p¼1.99x10 -05 , Gray's test). PD-1 Immune Checkpoint Cascade, was an independent predictor of progression (OR 2.85, p<0.05).
CONCLUSIONS: RNA sequencing delineates three molecular classes of NMIBC with different risks of progression to muscle invasion, compared to conventional histologic grading.
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MP65-12 ORGANOID 3D CULTURE SYSTEM FOR BLADDER CANCER MODELING
Victor Romanov, William Berg*, Terry Whyard, Wei Lee, Olga Povcher, Daniel Rittenberg, Wayne Waltzer, Stony Brook, NY INTRODUCTION AND OBJECTIVES: The absence of in vitro bladder cancer models recapitulating the diversity of urothelial tumors hinders our understanding of the disease pathogenesis and postpones development of the effective therapeutic modalities. Recent achievement in the development of 3D organoid systems enable stem or progenitor cells to form diverse, multicellular structures, that can selfrenew, self-organize, and differentiate. Development of 3D organoid culture from bladder urothelium provides an unique model for studying cancer. These structures can be genetically modified to mimic individual steps of bladder cancer tumorigenesis. 3D spheroids derived from bladder tumors can be directly used in preclinical applications METHODS: We developed 3D organoid cultures of urothelial cells that derived from experimental animals (mice) and human (ureter and bladder). Optimal conditions for preferential organoid development were determined. In addition 3D spheroids were established from surgical samples of papillary tumors. These structures were analyzed morphologically and biochemically. Tumor derived spheroids were also used for anti-cancer drug sensitivity testing.
RESULTS: We established procedure for generation organoids derived from single cell from bladder or ureter. These structures were characterized immunocytochemically and was shown that different types of urothelial cells were present. For bladder cancer derived organoid we used different preparative procedure based on the partial digestion of the tissue. In this case spheroids were formed from cellular conglomerates. Using tumor derived spheroids in drug sensitivity assay we have showed that potential drug-Clostridium perfringens toxin is superior as compared to currently exploited chemotherapeutical modalities for intravesical treatment.
CONCLUSIONS: Organoid 3D urothelial culture can be used for studying tumorigenesis in bladder cancer and for preclinical testing of potential chemotherapeutic agents. We report the development of a non-invasive molecular assay (UroSEEK) for detection of BC in patients with hematuria using DNA recovered from cells shed into urine. UroSEEK incorporates assays for assessment of mutations in 11 genes and copy number changes on 39 chromosome arms.
METHODS: Patients urine samples were collected prospectively in four institutions. The patients selected were referred for hematuria or lower urinary tract symptoms that prompted urine cytology examination to rule out BC. Urine samples were analyzed for mutation using three component assays: A multiplex PCR was used to detect mutations in regions of CDKN2A, ERBB2, FGFR3, HRAS, KRAS, MET, MLL, PIK3CA, TP53, and VHL. An amplification primer was used to amplify a 73-bp segment containing the region of TERT promoter. Aneuploidy was assessed with FastSeqS, which uses a single primer pair to amplifye38,000 loci scattered throughout the genome. Follow up data was obtained for each patient.
RESULTS: 570 patients were included in the study, 175 developed BC. The multiplex assay detected mutations in 68% of patients that developed BC. The most commonly altered genes were TP53 and FGFR3 (45% and 20% of the total mutations). Mutations in the TERT promoter were detected in 57% and aneuploidy was detected in 46% of patients that developed cancer, the most commonly altered chromosome arms were 5q, 8q, and 9p. When all 3 assays were combined, the sensitivity of UroSEEK was 83%.Combined with cytology UroSEEK was 95% sensitive and 93% specific. A total of 105 patients had "atypical" diagnosis on cytology. Eighteen patients developed a biopsy proven tumor. UroSEEK was positive in all 18 (100% sensitivity) with a mean lead time of 4 months (range 0 -18) from biopsy diagnosis. Cytology did not detect any of the low-grade tumors while UroSEEK detected 67% of these tumors. Cytology detected 50% of high-grade carcinomas while UroSEEK detected all of them.
CONCLUSIONS: UroSEEK raised the sensitivity of cytology from 43% to 95% for early detection of BC. UroSEEK was positive in all cases with atypical cytology that were subsequently diagnosed with BC. Prospective trials will be required to further demonstrate the utilty of integrating UroSEEK in screening strategies for BC detection in patients at risk. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e863
